Everence Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-2,760
| Closed | -$276K | – | 941 |
|
|
2024
Q3 | $276K | Buy |
+2,760
| New | +$276K | 0.02% | 625 |
|
|
2024
Q2 | – | Sell |
-2,760
| Closed | -$202 | – | 750 |
|
|
2024
Q1 | $202 | Buy |
+2,760
| New | +$202 | 0.01% | 716 |
|
|
2023
Q2 | – | Sell |
-2,760
| Closed | -$203 | – | 736 |
|
|
2023
Q1 | $203 | Buy |
+2,760
| New | +$203 | 0.02% | 678 |
|
|
2022
Q4 | – | Sell |
-4,424
| Closed | -$238K | – | 782 |
|
|
2022
Q3 | $238K | Hold |
4,424
| – | – | 0.02% | 598 |
|
|
2022
Q2 | $246K | Hold |
4,424
| – | – | 0.02% | 579 |
|
|
2022
Q1 | $310K | Hold |
4,424
| – | – | 0.02% | 549 |
|
|
2021
Q4 | $426K | Buy |
+4,424
| New | +$426K | 0.03% | 474 |
|
|
2018
Q4 | – | Sell |
-2,741
| Closed | -$469K | – | 436 |
|
|
2018
Q3 | $469K | Hold |
2,741
| – | – | 0.09% | 235 |
|
|
2018
Q2 | $354K | Buy |
2,741
+705
| +35% | +$91.1K | 0.07% | 279 |
|
|
2018
Q1 | $210K | Buy |
+2,036
| New | +$210K | 0.05% | 385 |
|